Linmarie Sikich, MD
Duke Clinical Research Institution (DCRI) · Duke · University of North Carolina, Chapel Hill
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Linmarie Sikich, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:15 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03522168 · Long-term Antipsychotic Pediatric Safety TrialDuke University · completed · Weight, Body · principal investigator
- Ph2NCT03242772 · Impact of Combined Medication and Behavioral Treatment for ASD & ADHDDuke University · terminated · Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder · principal investigator
- N/ANCT02353130 · Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine TreatmentUniversity of North Carolina, Chapel Hill · withdrawn · Autism Spectrum Disorders · principal investigator
- Ph2/Ph3NCT02212275 · Cortical Metrics in Intervention Trials With Autism Spectrum DisordersDuke University · withdrawn · Autism Spectrum Disorders · principal investigator
- N/ANCT02006381 · Oxytocin Levels in Typically Developing BoysUniversity of North Carolina, Chapel Hill · completed · Healthy Boys · principal investigator
- Ph1NCT01945957 · Brain Imaging of Intranasal Oxytocin Treatment in AutismUniversity of North Carolina, Chapel Hill · completed · Autism Spectrum Disorders · principal investigator
- Ph2NCT01944046 · Study of Oxytocin in Autism to Improve Reciprocal Social BehaviorsLinmarie Sikich · completed · Autism Spectrum Disorders · principal investigator
- Ph2NCT01731119 · Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and AdolescentsUniversity of North Carolina, Chapel Hill · completed · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder · principal investigator
- Ph4NCT01028820 · FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum DisordersUniversity of North Carolina, Chapel Hill · completed · Autism Spectrum Disorder · principal investigator
- Ph2NCT01006551 · Ziprasidone in Early Onset Schizophrenia Spectrum DisordersUniversity of North Carolina, Chapel Hill · completed · Schizophrenia · principal investigator
- N/ANCT00892580 · Biomarker and DNA Collection in Subjects Participating in Protocol 22003Seaside Therapeutics, Inc. · completed · Fragile X Syndrome · principal investigator
- Ph2NCT00846547 · Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum DisordersSeaside Therapeutics, Inc. · completed · Autism Spectrum Disorders · principal investigator
- N/ANCT00823368 · Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001Seaside Therapeutics, Inc. · completed · Fragile X Syndrome · principal investigator
- Ph4NCT00806234 · Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With AntipsychoticsJohns Hopkins University · completed · Psychotic Disorders · principal investigator
- Ph2NCT00788073 · Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X SyndromeSeaside Therapeutics, Inc. · completed · Fragile X Syndrome · principal investigator
- Ph2NCT00619190 · Study of Aripiprazole to Treat Children and Adolescents With AutismUniversity of North Carolina, Chapel Hill · completed · Autistic Disorder, Asperger Syndrome, Autism Spectrum Disorder · principal investigator
- Ph2NCT00617240 · Strategies to Reduce Antipsychotic-Associated Weight Gain in YouthUniversity of North Carolina, Chapel Hill · completed · Weight Gain · principal investigator
- Ph2NCT00617058 · Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and ClozapineUniversity of North Carolina, Chapel Hill · terminated · Weight Gain · principal investigator
- Ph2NCT00183339 · Early Intervention With Fluoxetine in AutismUniversity of North Carolina, Chapel Hill · completed · Autistic Disorder · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP50HD093074 · NICHD · DUKE UNIVERSITY · PI Geraldine Dawson · fiscal years 2017 to 2026Named on NCT03242772
- Preclinical CoreU54HD079124 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHERYL S MOY · fiscal years 2013 to 2019Named on NCT01945957
- Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)U01HD073984 · NICHD · DUKE UNIVERSITY · PI Linmarie Sikich · fiscal years 2012 to 2016Named on NCT01944046
- Functional Neuroimaging of Psychopharmacologic Intervention for AutismK23MH081285 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GABRIEL S DICHTER · fiscal years 2008 to 2012Named on NCT01028820
- 1/3-Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)R01MH080270 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Mark A Riddle · fiscal years 2008 to 2012Named on NCT00806234
- Gene-Brain-Behavior Relationships in AutismU54MH066418 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph Piven · fiscal years 2002 to 2006Named on NCT00183339
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.